SCHEMBL2393712

SCHEMBL2393712

CS(=O)(=O)c1ccc(C=O)cc1C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.42
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39
ABCB11 O95342 1/20 0.38
CCR2 P41597 2/20 0.37
TRPV4 Q9HBA0 1/20 0.37
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CA5B Q9Y2D0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16878950 0.79 APP (0.47) PIK3CDPIK3CAPIK3CBPIK3CGABCB11
SCHEMBL16878951 0.79 APP (0.47) PIK3CDPIK3CAPIK3CBPIK3CGABCB11
SCHEMBL27524707 0.77 CNR2 (0.39) PIK3CDPIK3CAPIK3CBPIK3CGALOX5AP
SCHEMBL12879058 0.77 PIK3CD (0.44) KIF11PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL7017664 0.77 ALDH1A3 (0.46) PIK3CDPIK3CAPIK3CBPIK3CGCA12
SCHEMBL29399275 0.77 ALDH1A1 (0.42) KIF11PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL9303098 0.77 ABCB11 (0.52) KIF11PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL5831189 0.77 KIF11 (0.44) KIF11PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL48553 0.77 ALDH1A1 (0.42) KIF11PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2395596 0.75 EGFR (0.50) KIF11PIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017608-B2 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2011-09-13 US disclosed
CN-100569770-C 5-phenyl thiazole derivant and they purposes as the PI3 kinase inhibitor NOVARTIS AG (CH) 2009-12-16 CN disclosed
EP-1608647-B1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-09 EP disclosed
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2006-07-06 US disclosed
CN-1780832-A 5-phenylthiazole derivatives and their use as PI3 kinase inhibitors NOVARTIS AG (CH) 2006-05-31 CN disclosed
EP-1608647-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS Novartis AG (CH) 2005-12-28 EP disclosed
WO-2004078754-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors MAP3K13, AKT3, MAP3K3 KIF11 1538/4885PIK3CD 42/4885PIK3CA 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.